This is a fast-growing provider of generic pharmaceutical products. From an investor’s standpoint, however, one would like to hear how the rapid increase in revenues can be turned into increased profitability by increasing Gross Margins – which is likely to mean changing the product mix, putting pressure on suppliers, increasing prices, or a mixture of all of these.
As an increasing number of private investors are now inevitably being drawn to AIM companies in which to invest their savings, a team of UKSA’s members has begun to examine selected AIM companies’ annual reports, with the objective of exposing directors’ reporting practices to public scrutiny by publishing our findings.
Full Clinigen Group review Clinigen plc
All UKSA AIM reviews here
